TCM
NBTX

Tybourne Capital Management’s Nanobiotix NBTX Stock Holding History

Tybourne Capital Management’s Portfolio NBTX Stock Details NBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-750,000
Closed -$10.3M – 27
2021
Q2 		$10.3M Hold
750,000
– – 0.22% 26
2021
Q1 		$11.3M Hold
750,000
– – 0.25% 28
2020
Q4 		$12.4M Buy
+750,000
New +$12.9M 0.26% 31

Other funds holding NBTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tybourne Capital Management's NBTX Position: Q3 2021 in Review

Tybourne Capital Management sold out of Nanobiotix (NBTX) in Q3 2021, closing a stake of 750,000 shares — an estimated $10.3M sold.

Tybourne Capital Management first reported a position in NBTX in Q4 2020 and held it in 3 quarters. The position peaked at $12.4M in Q4 2020. 9 funds tracked by Wall St. Rank hold NBTX as of Q3 2021.

  • Tybourne Capital Management reported no remaining Nanobiotix position as of Q3 2021 after selling out during the quarter.
  • Tybourne Capital Management sold 750,000 Nanobiotix shares in Q3 2021, an estimated $10.3M.
  • Tybourne Capital Management first reported a position in Nanobiotix in Q4 2020 and held it in 3 quarters.
  • Tybourne Capital Management's Nanobiotix position peaked at $12.4M in Q4 2020.
  • 9 funds tracked by Wall St. Rank held Nanobiotix as of Q3 2021.

Based on Tybourne Capital Management's 13F filing for Q3 2021, filed 27 Oct 2021.